{"id":391355,"date":"2015-07-31T00:00:00","date_gmt":"2015-07-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trtrus0415-biopharma-chronic-obstructive-pulmonary-disease-treatmenttrends-us-2015\/"},"modified":"2026-03-31T09:03:35","modified_gmt":"2026-03-31T09:03:35","slug":"trtrus0415-biopharma-chronic-obstructive-pulmonary-disease-treatmenttrends-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trtrus0415-biopharma-chronic-obstructive-pulmonary-disease-treatmenttrends-us-2015\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | TreatmentTrends | US | 2015"},"content":{"rendered":"<p>Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder and the third-leading cause of death in the United States. No currently available therapy treats the underlying cause of the disease, but a growing assortment of bronchodilators and anti-inflammatory agents are available to treat the symptoms, intensifying the competition in this market. With the availability of newer agents, including GlaxoSmithKline\/Theravance\u2019s Breo and GlaxoSmithKline\/Theravance\u2019s Anoro, the treatment landscape will have an impact on the long-established market leaders\u2014Boehringer Ingelheim\u2019s Spiriva, GlaxoSmithKline\u2019s Advair, and AstraZeneca\u2019s Symbicort. This report provides a comprehensive review of the current and anticipated management of COPD based on primary research with pulmonologists; it explores the use of short- and long-acting bronchodilators, these agents\u2019 patient and market share, the perceived strengths and weaknesses of the key brands, barriers to more-widespread uptake, and sales force performance. In addition, respondents are queried about their awareness of, and interest in, fixed-dose combinations in development for COPD.<\/p>\n","protected":false},"template":"","class_list":["post-391355","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-therapy-areas-respiratory","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391355\/revisions"}],"predecessor-version":[{"id":394478,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391355\/revisions\/394478"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}